In these contexts, we and others have shown that MSI and/or methylation of tumor-suppressor genes, including hMLH1, frequently occurs in the non-neoplastic gastric mucosa of patients with early GC [8,10,33] and that these molecular alterations can be potential markers for prediction of the development of GC [10,34]. The gene discussed is MLH1; the disease is gastric cancer.